Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Stephen T. Oh, MD, Jason Gotlib, MD MS, Sanjay Mohan, MD MSCI, Haris Ali, MD, Ekatherine Asatiani, MD, Francis Seguy, Feng Zhou, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-134574

Published: 2020

Journal Articles

miRNA Predictors of Response to DNA Methyltransferase Inhibitors

Amma Bosompem, MS, Yan Guo, PhD, Sanjay Mohan, MD, Begum Erdogan, MA, Muhammad Raza, MD, C. Michael Jones, MD FACP, Elizabeth A. Griffiths, MD, Annette S. Kim, MD PhD

Blood (2014) 124 (21): 1913.

https://doi.org/10.1182/blood.V124.21.1913.1913

Published: 2014

Journal Articles

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

Sawa Ito, MD, John Barrett, MD, Bipin N. Savani, MD, Madan Jagasia, MBBS, MS, Eolia Brissot, Samantha Miner, Nancy F. Hensel, Fariba Chinian, M.S., Keyvan Keyvanfar, BS, Minoo Battiwalla, MD MS, Michael R Savona, MD, Sanjay Mohan, MD, Mattias Carlsten, MD PhD, Pawel Muranski, MD, Stephen A. Strickland, MD MSCI

Blood (2014) 124 (21): 1047.

https://doi.org/10.1182/blood.V124.21.1047.1047

Published: 2014

Journal Articles

Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia

Joshua Lukenbill, D.O., Paul Elson, Sanjay Mohan, MD, Ramon V. Tiu, MD, Yogen Saunthararajah, MD, Leslie Farhat, Cassandra Kendeigh, Anjali Advani, MD, Edward A. Copelan, MD, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, MD, PhD, Mikkael A. Sekeres, MD, MS

Blood (2012) 120 (21): 4321.

https://doi.org/10.1182/blood.V120.21.4321.4321

Published: 2012

Journal Articles

Comparison of Prognostic Factors and Outcomes of Patients with Secondary Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML).

Sanjay Mohan, MD, Paul Elson, ScD, Cristina Rodriguez, MD, Rachid Baz, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Anjali Advani, MD, Jaroslaw P. Maciejewski, MD, PhD, Edward Copelan, MD, Mikkael A. Sekeres, MD

Blood (2007) 110 (11): 4292.

https://doi.org/10.1182/blood.V110.11.4292.4292

Published: 2007

NARROW

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

miRNA Predictors of Response to DNA Methyltransferase Inhibitors

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia

Comparison of Prognostic Factors and Outcomes of Patients with Secondary Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML).

Email alerts

ASH Publications

American Society of Hematology

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

miRNA Predictors of Response to DNA Methyltransferase Inhibitors

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia

Comparison of Prognostic Factors and Outcomes of Patients with Secondary Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only